Compounded vs Branded Low-Dose Testosterone for Women: The Clinical Comparison You Actually Need

Why There Is No FDA-Approved Testosterone Product for Women in the US

The absence of an approved female product is not an oversight. It reflects a regulatory and commercial history that has left women navigating off-label options with limited standardized guidance.

In 2004, the FDA advisory committee voted against approving Intrinsa, a 300 mcg/24-hour testosterone patch developed specifically for surgically menopausal women, citing insufficient long-term cardiovascular and breast safety data despite demonstrated efficacy over placebo. The patch was later approved in Europe but was withdrawn from that market in 2012 for commercial reasons, not safety findings.

That rejection created the current reality: the only testosterone products available in the US are dosed for men, and women who need therapy must either use a fraction of a male-dosed product, use a compounded formulation, or go without.

The WomanRx Testosterone Access Framework clarifies where each option sits:

| Option | Regulatory status | Dose calibrated for women | Quality assurance | |--------|------------------|--------------------------|-------------------| | Compounded cream/gel (US) | Off-label, state-regulated pharmacy | Yes, if correctly formulated | Variable; depends on pharmacy accreditation | | Male-dosed brand (e.g., AndroGel 1.62%, Testim) used at fractions | Off-label, FDA-approved drug at fraction of labeled dose | No (dose estimation required) | Consistent batch-to-batch | | Testosterone pellets | Off-label; not FDA-approved for any indication | No (wide dose variability reported) | Unregulated, irreversible short-term | | Intrinsa patch | Withdrawn from EU market; never available in US | Yes (300 mcg/24h) | N/A |

What the Evidence Actually Says: The 2019 Global Consensus

The most authoritative clinical document on this topic is the 2019 Global Consensus Statement on the Use of Testosterone Therapy for Women, a joint position statement endorsed by the Endocrine Society, the International Menopause Society, the British Menopause Society, and the Menopause Society (formerly NAMS), among others.

What the Consensus Recommends

The consensus reviewed data from 36 randomized controlled trials enrolling more than 8,000 women. Its core finding: testosterone therapy produces a statistically and clinically meaningful improvement in sexual desire, arousal, orgasm, and satisfaction in postmenopausal women with HSDD, compared with placebo. The mean increase in satisfying sexual events was approximately 0.5-1.0 events per month above placebo, which aligns with what women in trials reported as clinically noticeable.

The consensus explicitly states that testosterone should be used to achieve serum levels in the physiologic premenopausal range and should not exceed the upper limit of that range.

What the Consensus Does Not Recommend

The same document advises against:

• Testosterone pellet implants (dose cannot be titrated or reversed)
• Oral testosterone (hepatic first-pass metabolism creates supraphysiologic peaks)
• Use in premenopausal women except in specific circumstances, because trial data in that group is thin

The evidence gap in premenopausal women is real and should be named plainly. Women in their reproductive years, including those with PCOS or premature ovarian insufficiency, have historically been excluded from testosterone trials. Any use in that population is extrapolated from postmenopausal data.

Compounded Testosterone: What You Are Actually Getting

Compounded testosterone is prepared by a licensed compounding pharmacy, typically as a cream or gel, at doses designed for women. The most common concentrations prescribed are 0.5 mg to 2 mg per application, usually applied daily to inner thighs, labia majora, or forearm skin.

Advantages of Compounding

Dose flexibility is the main clinical argument for compounding. You can start at 0.5 mg/day and titrate upward in small increments based on serum testosterone levels and symptom response, something you cannot easily do with a male-dosed sachet containing 20.25 mg of testosterone per application.

Cost is a real consideration. A 30-day supply of compounded testosterone cream typically runs $30-$80 at an accredited compounding pharmacy, compared with $400+ per month for branded male-dosed gels without insurance.

Limitations You Should Know

Quality control varies. The FDA does not regulate compounded preparations the way it regulates manufactured drugs. A 2019 FDA analysis found that approximately one-third of compounded drug samples tested failed quality standards, including failures for potency (both under- and over-dose) and sterility. This means a cream labeled 1 mg/application may deliver 0.4 mg or 1.8 mg depending on the pharmacy's formulation practices.

PCAB (Pharmacy Compounding Accreditation Board) accreditation is the strongest available signal of quality, but accreditation is voluntary and not universally sought. When choosing a compounding pharmacy, ask specifically whether it holds PCAB accreditation and whether its testosterone formulations undergo third-party potency testing.

Absorption is also less predictable with compounded bases than with proprietary gel vehicles. Hydroalcoholic gels (the vehicle used in most branded products) have well-characterized transdermal absorption kinetics. Cream bases vary more by formulation.

Accidental Transfer Risk

Transdermal testosterone transfers to others through skin contact. This is not a theoretical concern. The FDA has issued warnings about virilization in children following accidental exposure to testosterone gels used by male household members. The same risk applies to female-dosed products. Wash hands after application, cover the site with clothing, and avoid skin-to-skin contact at the application site until it is fully dry.

Branded Male-Dosed Products Used Off-Label

When a prescriber writes testosterone for a woman using a branded product, she typically receives a male-dosed gel (e.g., AndroGel 1%, AndroGel 1.62%, or Testim) and is instructed to apply a small fraction of a sachet or pump depression. This approach has consistency advantages: the drug is manufactured under strict FDA quality standards with documented potency and bioavailability.

The problem is precision. AndroGel 1.62% delivers 20.25 mg per pump depression. A woman targeting 1.5 mg/day would need approximately 1/13 of one pump, which is nearly impossible to measure accurately. Most prescribers using this approach recommend applying a small, pea-sized amount and relying on serum monitoring to confirm the dose landed in the physiologic female range.

The Menopause Society's 2022 position statement on testosterone acknowledges this practical limitation and notes that compounded preparations, while lacking the regulatory backing of approved drugs, may be necessary to achieve appropriate female dosing.

How Doses Compare Across the Two Routes

The physiologic premenopausal total testosterone range in women is approximately 15-70 ng/dL, with values varying across the menstrual cycle. Published trials used the Intrinsa patch at 300 mcg/24 hours; this dose consistently produced mean serum levels in the 20-45 ng/dL range in postmenopausal women.

For compounded cream or gel, a dose of 1-2 mg/day applied to well-perfused skin typically produces serum levels in a similar range, but individual absorption varies enough that monitoring is not optional. Check serum total testosterone (ideally with a high-sensitivity assay, not the standard clinical lab assay, which has poor precision below 100 ng/dL) at 3-6 weeks after starting or after any dose change.

If levels are above 70 ng/dL, reduce the dose. If they are undetectable at 6 weeks on adequate therapy, consider a different application site or pharmacy.

Pregnancy, Lactation, and Contraception: A Required Section

Testosterone is contraindicated in pregnancy. This is not a relative contraindication. Testosterone is teratogenic in female fetuses, causing virilization of external genitalia. All women of reproductive potential who are prescribed testosterone must use reliable contraception. The contraceptive method must be confirmed before the first prescription is written.

Reproductive-Age Women

Premenopausal women using testosterone for any reason, including off-label use for low libido in the setting of PCOS or premature ovarian insufficiency, need a highly effective contraceptive method. Progesterone-only pills, copper IUDs, and levonorgestrel IUDs are all acceptable. Combined hormonal contraception is also acceptable if not otherwise contraindicated.

If pregnancy occurs while on testosterone, the drug must be stopped immediately and the prescribing clinician contacted the same day.

Lactation

Testosterone transfer into breast milk has not been adequately studied in humans. Given the potential for androgen effects on a nursing infant, the consensus position is that testosterone should not be used during lactation. Women who wish to use testosterone after completing breastfeeding should wait until milk supply is fully discontinued before starting.

Surgical Menopause

Women who have had bilateral oophorectomy before natural menopause experience an abrupt and more severe drop in testosterone than women undergoing natural menopause, because the ovaries produce roughly 25% of circulating testosterone directly and contribute to androgen precursor production. If you had surgical menopause before age 45, your testosterone deficiency may be more pronounced and symptom onset more sudden. This is a population where the evidence base for treatment is among the strongest, as many of the Intrinsa trial participants had surgically induced menopause.

Life-Stage Guide: Who Is This For, and Who Should Wait

Postmenopausal Women (Natural or Surgical)

This is the population with the strongest supporting evidence. The 2019 Global Consensus restricts its recommendation specifically to postmenopausal women with HSDD. If you have bothersome low sexual desire that is not explained by relationship factors, medications, depression, or an untreated genitourinary syndrome of menopause (GSM), a trial of transdermal testosterone at physiologic doses is a reasonable clinical step.

GSM should be treated first or concurrently. Vaginal dryness and dyspareunia can mimic or worsen HSDD, and local estrogen or ospemifene is the first-line treatment for GSM regardless of whether systemic testosterone is added.

Perimenopausal Women

Testosterone levels decline with age and are not tightly linked to menopause transition, but the symptom picture in perimenopause is complicated by fluctuating estrogen. The evidence base does not extend to perimenopausal women in any direct way. Some clinicians prescribe testosterone in this group when HSDD is persistent and other causes are addressed, but this is extrapolated practice, not guideline-supported practice. Women should know that clearly when making a decision.

Women with PCOS

Women with PCOS often have elevated androgens, not low ones. Testosterone supplementation is generally not appropriate in this population and could worsen hyperandrogenic symptoms including acne and hirsutism. PCOS-related low libido, when it occurs, is more likely driven by depression, body image concerns, or insulin resistance than by androgen deficiency.

Women with Premature Ovarian Insufficiency (POI)

POI before age 40 causes earlier and more complete loss of ovarian testosterone production. These women may have symptomatic androgen insufficiency at an age when most trials were not enrolling. Evidence is sparse. Any prescribing in this context is off-label extrapolation, and contraception is still required because ovarian function in POI is intermittent, not absent, and spontaneous pregnancy remains possible.

Women on Hormonal Contraception

Combined oral contraceptives increase sex hormone-binding globulin (SHBG), which binds testosterone and reduces free (bioavailable) testosterone. Some women on COCs report reduced libido partly as a consequence of this mechanism. Switching to a non-hormonal or progestin-only method may restore libido without adding testosterone. This is worth trying before prescribing testosterone in a reproductive-age woman on a combined pill.

Monitoring Protocol: What to Track and When

Monitoring is not negotiable. Supraphysiologic testosterone in women causes acne, oily skin, clitoral hypertrophy, voice changes, and potentially irreversible virilization with prolonged use. These are dose-dependent, not idiosyncratic, effects.

Recommended Monitoring Schedule

• Before starting: Total testosterone (baseline), lipid panel, hematocrit
• 3-6 weeks after starting: Total testosterone (to confirm levels are in the female physiologic range)
• 6 months: Total testosterone, lipid panel, hematocrit; assess symptom response
• Annually thereafter: Same labs; reassess indication

A high-sensitivity assay (LC-MS/MS) is preferred over immunoassay for measuring testosterone at female-range levels, because standard immunoassays are calibrated for male ranges and are unreliable below 100 ng/dL. Request the high-sensitivity method explicitly when ordering.

If after 6 months of therapy at adequate serum levels you have not noticed a meaningful change in sexual desire, testosterone is unlikely to be the solution and should be discontinued. A persistent HSDD diagnosis after ruling out testosterone deficiency should prompt evaluation for depression, relationship factors, medication side effects (especially SSRIs and SNRIs), thyroid dysfunction, and untreated GSM.

Safety: What We Know and What We Do Not

Established Safety Data

The 2019 consensus reviewed available data and found no statistically significant increase in adverse cardiovascular events, breast cancer, or severe androgenic adverse effects at physiologic doses over trial durations of up to 24 months. No serious safety signals emerged at female-physiologic doses in pooled trial data.

Mild androgenic effects, primarily acne and increased facial or body hair, occurred more frequently on testosterone than placebo but were generally mild and dose-dependent.

Where the Evidence Gaps Are Largest

Long-term safety data beyond 24 months does not exist in adequate quality. Breast cancer risk over 5-10 years of use is genuinely unknown. Women with a personal or strong family history of hormone-receptor-positive breast cancer should have a detailed discussion with their oncologist before starting testosterone. The consensus notes this uncertainty explicitly and does not provide a blanket contraindication, but it also does not provide reassurance.

Cardiovascular effects at female physiologic doses appear neutral in short-term trials, but no study has followed women for the decade-length periods that inform most cardiovascular risk assessment.

Women have been under-represented in androgen research. The clinical guidance available today is built on a smaller evidence base than exists for estrogen therapy in menopause, and women making this decision deserve to know that plainly.

Choosing Between Compounded and Branded: A Decision Guide

The choice is not about which product is superior in the abstract. It is about which option gives you the best chance of landing on a dose that produces serum levels in the physiologic female range, from a source you can verify is accurate.

Choose a compounded preparation if:

• You need precise, low-dose titration in increments of 0.5 mg or smaller
• Cost is a factor and you have access to a PCAB-accredited pharmacy with third-party potency testing
• Your prescriber has experience with female testosterone dosing protocols and can interpret high-sensitivity serum assays

Use a male-branded product at fractions of the labeled dose only if:

• You cannot access a reliable compounding pharmacy
• Your prescriber is comfortable with the imprecision of dosing a fraction of a male-calibrated product and commits to close serum monitoring
• You understand that batch-to-batch drug consistency is better, but dose consistency applied to skin is not

Avoid testosterone pellets. The dose cannot be adjusted after insertion, levels can swing supraphysiologic, and no reversal is possible until the pellet dissolves. The 2019 consensus and the Menopause Society do not recommend pellets for women.

Serum testosterone at 3-6 weeks is the only way to confirm your dose is working. Symptoms alone are not sufficient. A woman who feels better on testosterone could be experiencing a placebo effect at supraphysiologic levels, which produces short-term libido improvement but long-term virilization risk.